Powered by the Veeva Development Cloud, the
system brings together previously disparate functions to streamline
the medicinal development process and enhance operational
efficiencies
TEANECK,
N.J., March 11, 2025 /PRNewswire/ -- Cognizant
(Nasdaq: CTSH) and Boehringer Ingelheim announced today
the go-live of an end-to-end technology platform powered by the
Veeva Development Cloud, designed to accelerate the global
biopharmaceutical leader's delivery of life-transforming
treatments. The milestone marks the completion of Phase One of the
collaboration, which was first announced in 2023.
Boehringer's "One Medicine Platform," replaces over 20 legacy
platforms. The initiative unifies medicinal development processes
and data sources into a connected ecosystem, with the aim of
enhancing cross-functionality and operational efficiencies.
Cognizant, as the prime system integrator, began the Boehringer
Ingelheim project by codeveloping a program roadmap, agile
methodology, and implementation workflow. The overall scope of the
project entails services such as program management, system
architecture and design, training, integration, migration, testing
and validation. Cognizant partnered closely with Syneos Health
Consulting for business process engineering and with Veeva for
configuration and system architecture and design.
In Phase One, Cognizant successfully supported implementation
across clinical data, clinical operations, regulatory, and quality
functions, enabling Boehringer Ingelheim's move onto the unified
platform. This holistic approach is expected to streamline the
workflows of 15,000+ users working in Clinical Development
programs. In Phase Two, the collaborators look to further enhance
Boehringer's clinical operations practice and integrate additional
modules into its regulatory function.
"For years, Boehringer Ingelheim used multiple vendor systems
which lacked the ability to communicate with each other, which led
to complex workflows. The launch of our One Medicine Platform
revolutionizes our medicinal development processes and takes our
operational efficiencies to the next level," said Oliver Fink, Head Learning, Processes &
Digitalization, Global Quality Medicine at Boehringer
Ingelheim.
"We are pleased to achieve this program milestone in our
collaboration with Boehringer Ingelheim," said Gagan Syal, Head of Life Sciences, EMEA &
APAC, at Cognizant. "With this new system, Boehringer Ingelheim is
expected to resolve data challenges and latencies and speed up the
go-to-market of its products. Thanks to the close collaboration
across our teams, we have been able to execute this project in
record-time."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help
our clients modernize technology, reimagine processes, and
transform experiences so they can stay ahead in our fast-changing
world. Together, we're improving everyday life. See how at
www.cognizant.com or @cognizant.
About Boehringer Ingelheim
https://www.boehringer-ingelheim.com/ Boehringer Ingelheim
is a biopharmaceutical company active in both human and animal
health. As one of the industry's top investors in Research and
Development, the company focuses on developing innovative therapies
in areas of high unmet medical need. Independent since its
foundation in 1885, Boehringer takes a long-term perspective,
embedding sustainability along the entire value chain. More than
53,500 employees serve over 130 markets to build a healthier, more
sustainable, and equitable tomorrow. Learn more at
https://www.boehringer-ingelheim.com.
For more information, contact:
GlobalPR@cognizant.com
Logo -
https://mma.prnewswire.com/media/1794711/Cognizant_Logo_V1.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/boehringer-ingelheim-and-cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster-302397186.html